Yonke into ngeTicagrelor powder

1.Ticagrelor (274693-27-5)
2.Ticagrelor Igama loGama: iBrilinta
3. I-Ticagrelor: Indlela yokuSebenza
4.It ticagrelor (Brilinta) isebenza njani?
5. Uvavanyo lweTicagrelor-Clinical Trials
6.Siyiphi i-ticagrelor yezilwanyana esisetyenzisiweyo?
7. Indlela yokuthatha iTicagrelor (iBrilinta) ngokufanelekileyo
8.Ticagrelor Side Effects
9. Ziziphi ezinye iziyobisi ezichaphazela i-ticagrelor
10.Yimele ndiyazi ntoni ngokugcina nokulahla le mayeza?
11. Yintoni eyona nto ibaluleke kakhulu ukuba ndiyazi malunga ne-ticagrelor?
12.Iyiphi indleko yeRivaroxaban powder


Ividiyo ye-Ticagrelor powder


I.Ticagrelor powder Abalinganiswa basisiseko:

igama: I-ticagrelor powder
CAS: 274693-27-5
I-molecular Formula: C23H28F2N6O4S
Isisindo somzimba: 522.57
Melt Point: 140-142 ° C
Isitoreji sokugcina: -20 ° C
umbala: Powder


1. Ticagrelor(274693-27-5)aasraw

Zegazi lokuhlanganisa inhibitor Ticagrelor (274693-27-5) for sale.Ticagrelor (274693-27-5) is a inhibitor zegazi udibaniso, kugcina zegazi egazini lakho coagulating (ekunqandeni) ukuthintela egazi okungafunekiyo.

Ticagrelor (igama lezorhwebo Brilinta e-US, uBrilic and Possia kwi-EU) yi-platelet aggregation inhibitor eveliswa yi-AstraZeneca. Ngokungafani ne-clopidogrel, i-ticagrelor ayikho i-prodrug kwaye ayifuni ukusetyenziswa komzimba. I-Ticagrelor isetyenziselwa kunye ne-aspirin ukukhusela iingxaki ezinzulu okanye ezisongela ubomi ngentliziyo kunye nemithambo yegazi kubantu abanesifo senhliziyo okanye ubuhlungu obukhulu besifuba. Isetyenziselwa ukukhusela ama-clots egazi ekufakekeni kubantu abane-stonary stents (iitrabhu zensimbi zifakwe kwiimivenge zegazi ezivaliweyo ukuphucula ukuhamba kwegazi) eziye zahlaselwa yintliziyo okanye intlungu yesifuba. U-Ticagrelor useklasini yamayeza ebizwa ngokuba ngamayeza e-antiplatelet. Isebenza ngokuthintela iiplatelets (uhlobo lweseli yegazi) ukusuka ekuqokeleleni nasekuqulunqeni amaqhosha angabangela ukuhlaselwa intliziyo okanye ukubetha.


2. Ticagrelor Igama lebrand: Brilintaaasraw

I-Ticagrelor iyi-powder crystalline ene-solquility e-liquide ye-10 mcg / mL kwindawo yokushisa.
Iipilisi zeBrilinta ukuze ulawulo ngomlomo ziqulethe mg 90 of ticagrelor kunye izithako zilandelayo: mannitol, dibasic calcium phosphate, isodiyam wesitatshi glycolate, neselulosi hydroxypropyl, nemagnesium stearate, methylcellulose hydroxypropyl, titanium dioxide, talc, polyethylene ethers 400, kunye ne-nitric ferric yellow.


Igama leBicagrelor Igama loBhanka: iBrilinta.Ticagrelor yipoda ekhrisitini ene-solquility equeticity malunga ne-10 mcg / mL kwindawo yokushisa.


3. I-Ticagrelor: Indlela yokuSebenzaaasraw

Ticagrelor (Brilinta), ilungu cyclopentyltriazolopyrimidines yeklasi yemichiza omtsha (CPTP), nto leyo, nokwenza ngomlomo ngqo, bakhethe yaye reversibly zibopha P2Y12 receptor ochasene enqanda adenosine diphosphate (ADP) -mediated P2Y12 zegazi sokuvumela udibaniso. I-Ticagrelor ayiyikuthintela i-ADP ebophayo, kodwa xa iboshwe kwi-P2Y12 receptor inqanda ukutshintshiselwa kwesigxina se-ADP.
Ekubeni iiplatelet zithatha inxaxheba ekuqalweni kunye / okanye ukuguquka kweengxaki ze-thrombotic ze-atherosclerotic disease, ukuvinjelwa komsebenzi weplatelet kuye kwaboniswa ukunciphisa umngcipheko weziganeko zentliziyo ezifana nokufa, i-myocardial infarction okanye i-stroke.
I-Ticagrelor ineendlela ezongezelelweyo zesenzo, ukwandisa amazinga e-adenosine angapheliyo ngokuzivimbela i-nucleoside transporter-1 (ENT-1). I-Adenosine yenziwa kwindawo e-site ye-hypoxia kunye nomonakalo we-tissue ngokusebenzisa ukungcola kwe-adenosine tri- ne-di-phosphate (ATP ne-ADP). Njengoko i-adenosine degradation iyancitshitshiswa kwisithuba se-intracellular, ukuvinjelwa kwe-ENT-1 ngo-ticagrelor kwandisa ubomi obulicla i-adenosine kwaye ngoko kwandisa ingxubevange ye-extracellular yendawo ekubonelela ngayo iimpendulo ezongezelelweyo ze-adenosine zendawo. I-Ticagrelor ayinayo impembelelo echaphazelekayo kwi-adenosine receptors (A1, A2A, A2B, A3) kwaye ayinakuxilongwa kwi-adenosine. Adenosine sele zibhalwe ukuba inani yeziphumo eziquka: vasodilation, cardioprotection, inhibition zegazi, ngokuguquguqula kwe nokudumba kuFacebook dyspnoea, leyo negalelo iprofayili bezonyango belo ticagrelor.


4. Uthi ticagrelor (uBrilinta) usebenza njani?aasraw

I-Ticagrelor (i-Brilinta) iyakuthi ikhuphe i-plateletlet i-adenosine diphosphate (ADP) i-P2Y12 i-receptors ekhokelela ekunqandeni ngokukhawuleza kokusetyenziswa kweplatelet kunye nokuhlanganiswa. I-Clopidogrel iyakwenza kwezi zixhobo, nangona kunjalo, kuba "i-prodrug", utshintsho kwi-metabolite esebenzayo ithambekele ekubambeni okuncinci kwaye okungapheliyo kwe-plateagrelor (iBrilinta) .3, 5 Ukuguqulwa kwe-clopidogrel kwi i-metabolite esebenzayo idinga i-enzyme CYP2C19. Ngokumalunga ne-30-40% yabantu baseMāori, i-Pacific kunye no-Asia ubuye banciphisa umsebenzi we-CYP2C19 polymorphisms, xa kuthelekiswa ne-15% yabaseYurophu. Nangona kungabonakaliswa, i-ticagrelor (i-Brilinta) inokuba yinzuzo ethile, kuthelekiswa ne-clopidogrel, kubantu beli qela leentlanga (iMāori, Pacific kunye neAsia).


5. Uvavanyo lweTicagrelor-Clinical Trialsaasraw

(1) Inkqubela yeeklinikhi yeTicagrelor

Ukusebenza nokukhuseleko kwe-ticagrelor kuye kwavavanywa I-Platelet inhibition neziPhumo zeziPhumo (PLATO) isigaba-III sesilingo. Ulingo lwe-PLATO lwenziwe kwizigulane ezinokuphakama kwe-ST okanye kwi-AC-elevation ACS. I-18,624 isigulane (180-90 mg ngosuku) i-aspirin (300-600 mg ngosuku) okanye i-clopidrogel (75-75 mg ukulayisha umthamo, i-100 mg emva koko) kunye ne-aspirin (12-9.8 mg ngosuku) Iinyanga ze11.7. Isiphumo esiphumelele siphumo sasikufa ngenxa yezizathu zentliziyo. I-Myocardial infarction okanye i-stroke yancitshiswa kakhulu phakathi kwezigulane ezafumana ticagrelor xa kuthelekiswa nalabo bathatha i-clopidrogel (i-0.84% ne-0.001%; i-risk ratio (HR) XNUMX, P <XNUMX).
Nangona kunjalo, elinye iqela labagulane ababhalise eUnited States lenzeke ngakumbi nge-ticagrelor xa kuthelekiswa ne-clopidrogel (ubunobungozi be-1.27 xa kuthelekiswa nomngcipheko wengozi kwizigulane ezingekho kwi-US: 0.81). Idata ye-PLATO ibonise ukuba i-aspirin isilinganisi yayingu-≥300 mg kule nkqutyana yezigulane kwaye oko kungaba isizathu salolu hlobo lokuphendula.

(2) Isiphelo

Ngenxa yempembelelo yempilo ye-ACS, kunye nomthwalo wayo woqoqosho, i-P & T yezigqibo zifuna ukuchonga iindlela ezifanelekileyo zokunyangwa kwezi zifo ezikhubazayo nezokubulala.
I-Ticagrelor (i-Brilinta) yileyokuqala i-cyclopentyltriazolopyridine kwiklasi elitsha le-antiplatelets. I-Ticagrelor idibanisa ne-P2Y12 ADP receptor, evunyelwe ukunciphisa iziganeko zentliziyo ye-thrombotic kwizigulane ezine-ACS. I-Ticagrelor ayilona i-prodrug kwaye ayifuni ukusebenziselwa komzimba ukuvimbela ummkeli we-P2Y12; Nangona kunjalo, i-hematic metabolism iyadingeka ukuvelisa i-metabolite yayo esebenzayo.
Kwiqendu eliphambili-lwe-3 PLATO, Ticagrelor(I-Brilinta) yanciphisa kakhulu izinga lokuqala kokufunda kwesicatshulwa sokuphela kwesifo se-cardiovascular death, i-MI (ngaphandle kwe-MI), okanye i-stroke nge-clopidogrel. I-Ticagrelor iyancitshitshisa amaphulo okugqibela okufa kwe-cardiovascular and MI, ngokungafani nantlukwano kwi-clopidogrel.

I-Ticagrelor Mechanism of Action kwi-AASraw


I-Ticagrelor (i-Brilinta) ifundwe kwi-ACS ngokudibanisa ne-aspirin. Izondlo zokulondolozwa kwe-aspirin ngaphezu kwe-100 mg zinciphise ukusebenza kweTicagrelor. Amanqanaba okulondolozwa kwe-aspirin ngaphezu kwe-100 mg kufuneka agwenywe.
Njengamanye amanxusa e-antiplatelet, i-Ticagrelor ingabangela ibalulekileyo, ngamanye amaxesha abulale, aphephe. I-Ticagrelor ayifanele isetyenziswe kwizigulane ezinegazi elinomdla olusisigxina okanye imbali ye-hepatitisal hemorrhage. I-Ticagrelor ayifanele iqalwe kwizigulane ezicetywayo zokufumana uphando oluphuthumayo lwe-CABG.
Xa kunokwenzeka, unqande iTicagrelor ubuncinane iintsuku ze-5 ngaphambi kokuhlinzwa. Ukususwa kwegazi kumntu nawuphi na isigulane ophethe i-hypotensive kwaye usandula ukufumana i-coronary angiography, i-PCI, i-CABG, okanye enye inkqubo yokucwangcisa kwi-Ticagrelor. Ukuba kunokwenzeka, phatha igazi ngaphandle kokuyeka iTicagrelor. Ukumisa iTicagrelor kwandisa ingozi yeziganeko zentliziyo.
I-Ticagrelor (i-Brilinta) iyaphikiswa kwizigulane ezineembali zegazi kunye nokuphuma kwamathambo, njenge-peptic ulcer. I-Ticagrelor iphinde ichazwe kwizigulane ezinobungozi obukhulu be-hepatic ngenxa yokunyuka okubonakalayo ekuhleni. I-Ticagrelor ayizange ifundwe kwezi zi gulane. Ukuxakeka kwe-hepatic acceleration kwandisa umngcipheko wokuphuma kwamanzi ngenxa yokunciphisa ama-protective coagulation.
Ukusetyenziswa kwekliniki yeTicagrelor ixhaswa yiNkqubo yokuVavanywa koMngcipheko kunye neSicwangciso sokuNciphisa (REMS), esilungiselelwe ukwazisa abaqeqeshi bezempilo kunye nezigulane malunga neengozi ezinxulumene neTicagrelor, ingakumbi umngcipheko wegazi, kunye nesidingo sokuqinisekisa ukuba umthamo wokulondoloza i-aspirin, olawulwa kunye neTicagrelor, awugqithisi i-100 mg.


6. Ziyiphi i-ticagrelor yezidakamizwa ezisetyenzisiweyo?aasraw

♦ Ukusetyenziswa kweTicagrelor: Isetyenziselwa ukunciphisa ithuba lokuhlaselwa kwintliziyo, ukuphazamiseka nokufa kwabanye abantu.
♦ Ukusetyenziswa kweTicagrelor: Isetyenziselwa ukunciphisa ithuba lokucinywa kwe-stent emva kokuba i-stent ifakwe entliziyweni.
♦ Ukusetyenziswa kweTicagrelor: Unokunikezwa ngezinye izizathu. Thetha nogqirha.


7. Njani Yise e Ticagrelor(Brilinta) ngokufanelekileyo?aasraw

(1) Ticagrelor(Brilinta) ulwazi lwe-dosing

Ukwenza i-Adult Dose kwi-Coronary Syndrome efanelekileyo.
Ukulandela umcimbi we-coronary syndrome (ACS):
Ukulayisha idosi: 180 mg ngomlomo kanye
Isondlo se-Maintenance: 90 mg ngomlomo kabini ngosuku ngeminyaka ye-1
Umthamo wesondlo emva komnyaka we-1: 60 mg ngomlomo kabini ngosuku
Amazwana:
- Esi sidakamizwa kufuneka sithathwe ngokubambisana ne-aspirin 75 kwi-100 mg ngomlomo ngosuku.
-Ngokuba ubuncinane iinyanga ze-12 ezilandelayo kwi-ACS, eli liyeza liphezulu kune-clopidogrel.
Ukusetyenziswa:
-Ukunciphisa izinga lokufa kwegazi, i-myocardial infarction, kunye nokubetha kwezigulane ezine-acon coronary syndrome (ACS) okanye imbali ye-myocardial infarction.
-Ukunciphisa izinga le-stent thrombosis kwizigulane ezithandekayo unyango lwe-ACS.
Ukusetyenzwa koMntu oMdala wokuThusela iziganeko ze-Atherothrombotic:
Ukulandela umcimbi we-coronary syndrome (ACS):
Ukulayisha idosi: 180 mg ngomlomo kanye
Isondlo se-Maintenance: 90 mg ngomlomo kabini ngosuku ngeminyaka ye-1
Umthamo wesondlo emva komnyaka we-1: 60 mg ngomlomo kabini ngosuku
Amazwana:
- Esi sidakamizwa kufuneka sithathwe ngokubambisana ne-aspirin 75 kwi-100 mg ngomlomo ngosuku.
-Ngokuba ubuncinane iinyanga ze-12 ezilandelayo kwi-ACS, eli liyeza liphezulu kune-clopidogrel.
Ukusetyenziswa:
-Ukunciphisa izinga lokufa kwegazi, i-myocardial infarction, kunye nokubetha kwezigulane ezine-acon coronary syndrome (ACS) okanye imbali ye-myocardial infarction.
-Ukunciphisa izinga le-stent thrombosis kwizigulane eziye zanyamekela unyango lwe-ACS.

(2) njani oku I-Ticagrelor ingcono?

Sebenzisa i-ticagrelor njengoko iyalwe ngugqirha wakho. Funda zonke iinkcukacha ezinikwe zona. Landela yonke imiyalelo ngokufutshane.
♦ Thatha i-ticagrelor ngexesha elinye.
♦ Thatha okanye ngaphandle kokutya.
♦ Ukuba awukwazi ukugwinya i-tablet yonke, ithebhulethi inokuchotshozwa kwaye ixutywe ngamanzi.
♦ Phuza nje emva kokuxuba. Gcwalisa iglasi ngamanzi, ugxobhoze, uphuze.
♦ Labo abanesibindi zokutya bangasebenzisa ithebhulethi. Yichitha i-tablet kwaye uyixube ngamanzi.
♦ Ukucoca ityhubhu yokutya emva kokuba i-ticagrelor inikwe.
♦ Ukuze ufumane inzuzo enkulu, ungaphuthelwa amaxabiso.
♦ Qhubeka uthatha i-ticagrelor njengoko uxelelwe ngugqirha okanye omnye umboneleli wezempilo, nokuba uziva kakuhle.
Yintoni endiyenzayo xa ndiphosakele ticagrelor dose?
♦ Yeka i-ticagrelor dose ephosakeleyo uze ubuye kwixesha lakho eliqhelekileyo.
♦ Ungathathi i-2 ticagrelor idayithi ngexesha elinye okanye amayeza angaphezulu.

IFrame

(3) Ndingayithatha njani i-ticagrelor (Brilinta)?

Thatha ngqo njengoko ugqirha wakho ugqirha. Ungathathi kwixabiso elikhulu okanye elincinci okanye ixesha elide kunconywayo. Landela izikhokelo kwiileyibrari yakho yemithi.
I-Ticagrelor kufuneka ithathwe kunye ne-aspirin. Landela imiyalelo yegqirha yakho malunga nokuba ufuna i-aspirin engakanani. I-Ticagrelor ingathathwa kunye okanye ngaphandle kokutya. Thatha iyeza ngexesha elifanayo ngalunye suku.
Ngenxa yokuthi ticagrelor igcina igazi lakho lingagxininisi (ukucima) ukukhusela ama-clots angafunekiyo, le nyeza inokukwenza kube lula kuwe ukuba uphume igazi, kwimeko yokulimala okuncane. Xhagamshelana nogqirha okanye ufune unyango lwengxamisekileyo ukuba unayo nayiphi na igazi eliya kumisa.
Ukuba udinga utyando okanye umsebenzi wamazinyo, xelela udokotela ogqirha okanye wamazinyo ngaphambi kwexesha osebenzisa i-ticagrelor. Ungadinga ukuyeka ukusebenzisa iyeza okungenani iintsuku ze-5 ngaphambi kokuhlinzwa, ukukhusela ukuphuma kwegazi. Landela imiyalelo yakho ugqirha uze uqale ukuthatha i-ticagrelor kwakhona ngokukhawuleza.
Ungayeki ukuthatha i-ticagrelor ngaphandle kokuqala ukuthetha nodokotela wakho, nangona unempawu yokuphuma kwegazi. Sebenzisa i-ticagrelor rhoqo ukufumana inzuzo enkulu. Fumana i-odokotela yakho igqityiwe ngaphambi kokuba uphume ngokupheleleyo kweyeza. Ukuyeka i-ticagrelor kunokunyusa umngcipheko wakho wokuhlaselwa yintliziyo okanye ukubetha. Gcina kwiqondo lokushisa elisekude kumanzi kunye nobushushu.

(4) Yintoni okufanele ndiyiphephe xa sithatha i-ticagrelor(Brilinta)?

Ukusela utywala ngelixa uthabatha i-aspirin kunokunyusa umngcipheko wokuphuma kweesisu.
Gwema imisebenzi enokunyusa umngcipheko wokukhupha okanye ukulimala. Sebenzisa unonophelo olongezelelweyo ukukhusela ukuphuma kwegazi xa ucafa okanye uhlamba amazinyo akho.
Nakuba kuthatha i-ticagrelor kunye ne-aspirin, gwema ukusebenzisa amayeza entlungu, umkhuhlane, ukuvuvukala, okanye iimpawu ezibandayo / ezikhuhlane. Zingenakho izithako ezifana ne-aspirin (njenge-salicylates, ibuprofen, ketoprofen, okanye naproxen). Ukuthatha iimveliso ezithile kunye kunokubangela ukuba ube ne-aspirin eninzi enokunyusa umngcipheko wegazi.


8. Ticagrelor Imiphumelaaasraw

ISEXWAYISO / UKUQONDWA: Nangona kungenakwenzeka, abanye abantu banokubi kwaye maxa wambi babulalayo nemiphumela emibi ye-ticagrelor xa uthatha i-ticagrelor. Tshela ugqirha wakho okanye ufumane uncedo lwezokwelapha ngokukhawuleza ukuba unayo nayiphi na impawu okanye iimpawu ezilandelayo ezinxulumene nemiphumo emibi kakhulu yecala le-ticagrelor:
♦ Izibonakaliso zempembelelo, njengokugqithisa; mihlathi; ukubetha; obomvu, ukuvuvukala, ukukhenkceza, okanye ukukhupha isikhumba kunye okanye ngaphandle kwemfiva; ukujikeleza; ukuqina kwisifuba okanye emqaleni; ingxaki yokuphefumla, ukugwinya, okanye ukuthetha; ukuthoba okungavamile; okanye ukuvuvukala komlomo, ubuso, imilomo, ulwimi, okanye umqala.
♦ Iimpawu zokuphuma kwegazi njengokuphosa igazi okanye ukuphosa okubukeka njengeendawo zekhofi; ukukhwehlela igazi; igazi kumchamo; kumnyama, obomvu, okanye iitars; ukuphuma kumagundane; ukuphuma kwintsholongwane engavamile; izibhamu ngaphandle kwesizathu okanye ukuba zikhule; okanye nayiphi na ukuphuma kwegazi okubi kakhulu okanye ukuba awukwazi ukuyeka.
♦ Ubuthakathaka kwicala le-1 yomzimba, ukukhathazeka ukuthetha okanye ukucinga, utshintshe ukulinganisela, ukuhlahlela kwelinye icala lobuso, okanye ukujonga amehlo.
♦ Intloko yesifo esibi.
♦ Ukuphefumula okufutshane.
♦ Ukunyaniseka kwentliziyo.
♦ Intliziyo engabonakali yinto eqhelekileyo.

I-Ticagrelor - Izilingo zeCliniki: I-Ticagrelor (i-Brilinta) ifundwe kwi-ACS ngokudibanisa ne-aspirin. Izondlo zokulondolozwa kwe-aspirin ngaphezu kwe-100 mg zinciphise ukusebenza kweTicagrelor. Amanqanaba okulondolozwa kwe-aspirin ngaphezu kwe-100 mg kufuneka agwenywe


9. Ziziphi ezinye iziyobisi ezichaphazela i-ticagrelor?aasraw

Maxa wambi akukhuselekanga ukusebenzisa amachiza athile ngexesha elifanayo. Ezinye iziyobisi zingathintela amanqanaba akho egazi nezinye izilwanyana ozithathayo, ezinokunyusa imiphumo emibi okanye ukwenza amayeza angasebenzi kakuhle.
Tshela ugqirha wakho malunga nawo onke amayeza akhoyo. Amachiza amaninzi anokusebenzisana ne-ticagrelor, ngakumbi:
♦ unyango olungenakusebenza;
♦ unyango lwe-antiviral ukuphatha i-HIV okanye i-AIDS;
♦ igazi elincinci;
♦ amayeza e-cholesterol;
♦ intliziyo okanye unyango lwegazi;
♦ amayeza opioid;
♦ unyango lwezobisi; okanye
• isifo sofuba.


10. Yintoni endimele ndiyazi malunga nokugcinwa nokulahla le mayeza?aasraw

Gcina le nyilisi kwisitya, ivalwe ngokuqinileyo, kwaye ingafiki kubantwana. Yigcine kwiqondo lokushisa lokushisa kwaye kude nobushushu obuninzi kunye nobumanzi (kungekhona kwindawo yokuhlambela).
Amachiza angenagunya kufuneka alahlwe ngendlela ezizodwa zokuqinisekisa ukuba izilwanyana, abantwana kunye nabanye abantu abanakuzidla. Nangona kunjalo, akufanele uhlalutye le mayeza kwizindlu zangasese. Kunoko, indlela efanelekileyo yokulahla amayeza akho ngeprogram yokubuyisela iyeza. Thetha kumakhomistiya okanye qhagamshelana nomnyango wendawo yokulahla / uhlaziyo kwakhona ukuze ufunde malunga neenkqubo zokubuyisela kuluntu. Khangela i-website ye-FDA ye-Safe Disposal of Medicines ngolwazi olungakumbi ukuba awukwazi ukufikelela kwinkqubo yokubuyisela.
Kubalulekile ukugcina onke amayeza angabonakaliyo kunye nokufikelela kubantwana njengezikhonkwane ezininzi (ezifana neepilisi zeveki zeeveki kunye nezokwamahla, i-creams, i-patches, kunye ne-inhalers) abaxhomeki abantwana kunye nabantwana abancinci bangabavula ngokulula. Ukukhusela abantwana abancinci besetyhefu, soloko uvale iifake zokuphepha kwaye ubeke ngokukhawuleza loo mayeza kwindawo ekhuselekileyo - enye ephakanyisiwe kwaye ingabikho emehlweni abo kwaye ifinyelele.

umsebenzi ticagrelor kunye nedosi Ticagrelor: Ticagrelor (274693-27-5) is a inhibitor zegazi udibaniso, kugcina zegazi egazini lakho coagulating (ekunqandeni) ukuthintela egazi okungafunekiyo.


11. Yintoni eyona nto ibaluleke kakhulu ukuba ndiyazi malunga ne-ticagrelor (Brilinta)?aasraw

I-Ticagrelor igcina igazi lakho lingagxininisi (ukucima) ukukhusela iifutha zegazi ezingafunwayo ezinokuthi zenzeke ngeentliziyo ezithile okanye iimeko zeetya zegazi. Ngenxa yeli nyathelo lonyango, i-ticagrelor ingenza kube lula ukuba uphepha, kwinto yokulimala okwenzakala. Xhagamshelana nogqirha wakho okanye ufuna unyango lwengxamisekileyo ukuba unayo igazi elingayi kumisa.
Ungaphinda uchithe igazi ngaphakathi ngaphakathi emzimbeni wakho, njengesisu sakho okanye emathunjini. Biza ugqirha wakho ngokukhawuleza ukuba unesigodlo esimnyama okanye esinokugawula igazi, okanye ukuba ukhwehlela igazi okanye uhlanza olubukeka njengeziko lekhofi. Ezi zinokuba yimpawu zokuphuma kumgudu wakho wokugaya.
Ngelixa uthatha i-ticagrelor, ungathathi i-aspirin okanye ezinye i-NSAID (iziyobisi ezingenayo i-steroidal anti-inflammatory) ngaphandle kweengcebiso zakho. I-NSAID ziquka ibuprofen (Advil, Motrin), naproxen (Aleve, Naprosyn, Naprelan, Treximet), i-celecoxib (iCelebrex), i-diclofenac (iCataflam, i-Voltaren), i-indomethacin (i-Indocin), i-meloxicam (i-Mobic) kunye nabanye.
I-Ticagrelor inokubangela ukuba uphumle ngokulula ngakumbi, ngakumbi ukuba unayo: imbali yeengxaki zegazi, utyando okanye unyango olungxamisekileyo, isifo esichaphazela imithwalo yegazi kwingqondo yakho, imbali yesisu okanye ukuphuma kwamathumbu emathunjini, okanye ukuba u-65 okanye badala.
Amachiza amaninzi (kuquka amanye amayeza amaninzi kunye nemveliso yemveliso) anokusebenzisana ne-ticagrelor. Kubalulekile ukuxelela ugqirha wakho malunga nawo onke amayeza osanda kusebenzisa. Buza ugqirha wakho ngaphambi kokuthatha nayiphi na iyeza kwiintlungu, isifo samathambo, umkhuhlane, okanye ukuvuvukala. La mayeza angachaphazela ukuxilwa kwegazi kwaye inokunyusa umngcipheko wokuphuma kweesisu. Naluphina ugqirha, udokotela wamazinyo, ugqirha ogqirha, okanye omnye umniki-nkonzo ogqirha unyango omele uyazi ukuba uthatha i-ticagrelor.


12. Ndingafumana phi ulwazi olungaphezulu?aasraw

Khumbula, gcina lo kunye nawo onke amayeza ngaphandle kokufikelela kubantwana, ungaze wabelane ngamayeza akho nabanye, kwaye usebenzise le mayeza kuphela ngenjongo echaziweyo.
Yonke imizamo yenziwe ukuba kuqinisekiswe ukuba ulwazi olunikeziwe AASraw up-to-date, kwaye uzalise, kodwa akukho siqinisekiso esenziwe kuloo nto. Ulwazi lweziyobisi oluqulethwe apha lungaba luncedo. Inkcazelo ye-AASraw ihlanganiswe ukuze isebenziswe ngabasebenzi bezempilo kunye nabathengi e-United States kwaye ngoko i-AASraw ayifuni ukuba isebenzise ngaphandle kwe-United States ifanelekile, ngaphandle kokuba iboniswe ngenye indlela. Ulwazi lwezilwanyana lwe-AASraw aluvumeli iziyobisi, ufumanisa izigulane okanye ucebisa unyango. Ulwazi lweziyobisi lwe-AASraw luyimithombo yolwazi eyenzelwe ukuncedisa abasebenzi bezempilo abanemvume ekunyamekeleni izigulane zabo kunye / nokuba bakhonze abathengi bebukela le nkonzo njengencediso, kwaye kungabi yinto ethatha indawo, ubuchule, ubuchule, ulwazi kunye nesigwebo sabasebenzi bezempilo. Ukungabikho kwesilumkiso kwisilwanyana esisinikiweyo okanye inkunkuma engekho nto kufuneka kuthethwe ukuba kuboniswe ukuba izilwanyana okanye iziyobisi zikhuselekile, zichanekile okanye zifanelekile naziphi na iziguli. I-AASraw ayithathi naluphi na uxanduva malunga nayiphi na inkalo yempilo elawulwa ngoncedo ngolwazi AASraw inikezela. Ingcaciso equlethwe apha ayihloselwe ukugqithisa zonke izinto ezisetyenziswayo, izikhokelo, izilumkiso, izilumkiso, ukusebenzisana kwezidakamizwa, ukuphendulwa kwezidakamizwa, okanye iziphumo ezimbi. Ukuba unemibuzo malunga neziyobisi othabathayo, jonga ugqirha wakho, umongikazi okanye umkhompiki.

Ukujoyina i-Platelet Aggregation Inhibitor Ticagrelor (274693-27-5) ukuthengiswa - AASraw.Usebenzisa kwakho umxholo onikezelwe kule nkonzo kubonisa ukuba ufundile, uqondayo kwaye uyavumelana neSivumelwano seLayisense yeMvume-sokugqibela, esinokufikelela ngokuchofoza kwesi sixhobo.

Ukusebenzisa kwakho umxholo onikezelwe kule nkonzo kubonisa ukuba ufundile, uqondayo kwaye uyavumelana nesiVumelwano sokuPhathwa kweMvume yoMsebenzisi, esingasifumana ngokuchofoza kwesi sixhobo. Joyina i-Platelet Aggregation Inhibitor Ticagrelor (274693-27-5) ukuthengisa -AASraw.


0 azithandayo
3098 Views

Ungathanda

Amagqabantshintshi zivaliwe.